Publications by authors named "H Shimazu"
Article Synopsis
- - Median arcuate ligament syndrome results in the celiac artery being compressed, leading to reduced blood flow and potential aneurysm formation in the pancreatic area; it was observed in six cases during the COVID-19 pandemic.
- - Patients experienced abdominal pain 3 to 9 days after COVID-19 onset, although none required oxygen, and diagnoses were confirmed using contrast-enhanced CT scans showing hemorrhage and aneurysms.
- - While rare, retroperitoneal hemorrhage related to this syndrome may be exacerbated by COVID-19, causing complications like duodenal stenosis and portal vein thrombosis in some patients.
Background: The global impact of the coronavirus disease 2019 (COVID-19) pandemic has resulted in significant morbidity and mortality. Immunocompromised patients, particularly those treated for B-cell lymphoma, have shown an increased risk of persistent infection with SARS-CoV-2 and severe outcomes and mortality. Multi-mutational SARS-CoV-2 variants can arise during the course of such persistent cases of COVID-19.
View Article and Find Full Text PDFObjectives: Imbalanced activities between dopamine D and D signals in striatal striosome-matrix system have been proposed as a cause of dystonia symptoms. The aim of this study was to assess the therapeutic effects of dual dopaminergic modulation (DDM) with l-DOPA and chlorpromazine (CPZ) in patients with idiopathic cervical dystonia (CD).
Methods: We enrolled 21 patients with CD who responded poorly to botulinum toxin treatment.
Article Synopsis
- Immunocompromised COVID-19 patients experience longer viral shedding compared to those with normal immunity, but there's no universal guideline for safely ending their isolation as of August 2023.
- Comprehensive evaluations considering factors like mutant strains and patient immunity are crucial, and consulting infectious disease specialists is advised for better management.
- The study developed new isolation criteria based on patient classifications and clinical symptoms, highlighting the need for continuous updates using real-world data to improve these guidelines for non-specialists.
Background: The efficacy of antiviral drugs that neutralize antibody drugs and fight against SARS-COV-2 is reported to be attenuated by genetic mutations of the virus in vitro. When B-cell immunocompromised patients are infected with SARS-COV-2, the infection can be prolonged, and genetic mutations can occur during the course of treatment. Therefore, for refractory patients with persistent COVID-19 infection, genomic analysis was performed to obtain data on drug resistance mutations as a reference to determine which antiviral drugs and antibody therapies might be effective in their treatment.
View Article and Find Full Text PDF